A decision by Canada’s Drug Agency will make it more difficult for Canadians to access a drug shown to slow Alzheimer’s disease in some people, says an Ottawa cognitive neurologist and researcher. Dr.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results